Relation of Maximum Lifetime Body Mass Index with Age at Hemodialysis Initiation and Vascular Complications in Japan.
Diabetic retinopathy
End-stage renal disease
Hemodialysis initiation
Maximum lifetime body mass index
Obesity management
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
01
2021
accepted:
16
06
2021
pubmed:
14
9
2021
medline:
4
1
2022
entrez:
13
9
2021
Statut:
ppublish
Résumé
The aim of this study was to investigate the association of the maximum lifetime body mass index (max BMI) with hemodialysis initiation and comorbidities in Japanese hemodialysis patients. In a retrospective cross-sectional study on 724 hemodialysis patients, max BMI, age at hemodialysis initiation, and comorbidities including sleep apnea syndrome, cerebro-cardiovascular diseases, and proliferative diabetic retinopathy (PDR) were analyzed. Early hemodialysis initiation was defined as age <50 years. Diabetes patients showed a higher max BMI and prevalence of atherosclerotic diseases than nondiabetes patients, despite almost the same age at hemodialysis initiation. Patients with early hemodialysis initiation showed higher male ratio, prevalence of PDR, and max BMI than those with later initiation, despite almost equal prevalence of diabetes. Receiver-operating characteristic curve analysis determined a max BMI of 28.4 kg/m2 as a reliable cutoff value for predicting early hemodialysis initiation, and this parameter was identified as an independent predictor of early hemodialysis initiation using bivariate logistic regression analysis. Vitrectomy for PDR also tended to contribute independently to early hemodialysis initiation. A high max BMI contributed to early hemodialysis initiation independent of diabetes. Furthermore, PDR was associated with a high max BMI and early hemodialysis initiation. These results suggest that weight reduction in young chronic kidney disease patients with obesity may prevent hemodialysis and blindness.
Identifiants
pubmed: 34515199
pii: 000518049
doi: 10.1159/000518049
pmc: PMC8546452
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-558Informations de copyright
© 2021 The Author(s) Published by S. Karger AG, Basel.
Références
J Am Soc Nephrol. 2006 Jun;17(6):1695-702
pubmed: 16641153
Hypertension. 2010 Nov;56(5):901-6
pubmed: 20837881
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Kidney Int Rep. 2017 Jan 23;2(2):251-260
pubmed: 29142961
Int J Obes (Lond). 2005 Sep;29(9):1115-20
pubmed: 15925953
Ann Intern Med. 2006 Jan 3;144(1):21-8
pubmed: 16389251
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
J Diabetes Investig. 2010 Oct 19;1(5):212-28
pubmed: 24843435
J Am Soc Nephrol. 2006 May;17(5):1453-9
pubmed: 16597682
Prev Chronic Dis. 2017 Aug 17;14:E67
pubmed: 28817790
Front Med. 2017 Sep;11(3):340-348
pubmed: 28791668
J Nutr. 2004 Oct;134(10):2673-7
pubmed: 15465765
J Atheroscler Thromb. 2014;21(8):784-98
pubmed: 24671110
Diabetologia. 2003 Nov;46(11):1483-8
pubmed: 14534780
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Lancet Diabetes Endocrinol. 2014 May;2(5):417-26
pubmed: 24795255
Ophthalmologica. 2016;235(4):225-32
pubmed: 27082736
Obes Surg. 2012 May;22(5):677-84
pubmed: 22367008
N Engl J Med. 2006 Aug 24;355(8):763-78
pubmed: 16926275
Cochrane Database Syst Rev. 2021 Mar 30;3:CD013119
pubmed: 33782940
Endocr Rev. 1997 Feb;18(1):4-25
pubmed: 9034784
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Kidney Int Suppl. 2000 Sep;77:S113-9
pubmed: 10997700
Obes Res Clin Pract. 2013 Mar-Apr;7(2):e139-e145
pubmed: 24331775
J Gastroenterol. 2014 Jan;49(1):57-63
pubmed: 23595611
Ann Gastroenterol Surg. 2019 Aug 26;3(6):638-647
pubmed: 31788652